Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Unfolded Protein Response: A Novel Therapeutic Target for Poor Prognostic BRAF Mutant Colorectal Cancer.
Forsythe N, Refaat A, Javadi A, Khawaja H, Weir JA, Emam H, Allen WL, Burkamp F, Popovici V, Jithesh PV, Isella C, Labonte MJ, Mills IG, Johnston PG, Van Schaeybroeck S. Forsythe N, et al. Among authors: jithesh pv. Mol Cancer Ther. 2018 Jun;17(6):1280-1290. doi: 10.1158/1535-7163.MCT-17-0603. Epub 2018 Feb 26. Mol Cancer Ther. 2018. PMID: 29483217 Free PMC article.
A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer.
Allen WL, Stevenson L, Coyle VM, Jithesh PV, Proutski I, Carson G, Gordon MA, Lenz HJ, Van Schaeybroeck S, Longley DB, Johnston PG. Allen WL, et al. Among authors: jithesh pv. Mol Cancer Ther. 2012 Jan;11(1):119-31. doi: 10.1158/1535-7163.MCT-11-0510. Epub 2011 Oct 25. Mol Cancer Ther. 2012. PMID: 22027693 Free PMC article.
Identification of galanin and its receptor GalR1 as novel determinants of resistance to chemotherapy and potential biomarkers in colorectal cancer.
Stevenson L, Allen WL, Turkington R, Jithesh PV, Proutski I, Stewart G, Lenz HJ, Van Schaeybroeck S, Longley DB, Johnston PG. Stevenson L, et al. Among authors: jithesh pv. Clin Cancer Res. 2012 Oct 1;18(19):5412-26. doi: 10.1158/1078-0432.CCR-12-1780. Epub 2012 Aug 2. Clin Cancer Res. 2012. PMID: 22859720 Free PMC article.
ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer.
Van Schaeybroeck S, Kalimutho M, Dunne PD, Carson R, Allen W, Jithesh PV, Redmond KL, Sasazuki T, Shirasawa S, Blayney J, Michieli P, Fenning C, Lenz HJ, Lawler M, Longley DB, Johnston PG. Van Schaeybroeck S, et al. Among authors: jithesh pv. Cell Rep. 2014 Jun 26;7(6):1940-55. doi: 10.1016/j.celrep.2014.05.032. Epub 2014 Jun 12. Cell Rep. 2014. PMID: 24931611 Free article.
Transcriptional subtyping and CD8 immunohistochemistry identifies poor prognosis stage II/III colorectal cancer patients who benefit from adjuvant chemotherapy.
Allen WL, Dunne PD, McDade S, Scanlon E, Loughrey M, Coleman H, McCann C, McLaughlin K, Nemeth Z, Syed N, Jithesh P, Arthur K, Wilson R, Coyle V, McArt D, Murray GI, Samuel L, Nuciforo P, Jimenez J, Argiles G, Dienstmann R, Tabernero J, Messerini L, Nobili S, Mini E, Sheahan K, Ryan E, Johnston PG, Van Schaeybroeck S, Lawler M, Longley DB. Allen WL, et al. JCO Precis Oncol. 2018 Jun 13;2018:PO.17.00241. doi: 10.1200/PO.17.00241. JCO Precis Oncol. 2018. PMID: 30088816 Free PMC article.
Targeting treatment-resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathway.
McClements L, Yakkundi A, Papaspyropoulos A, Harrison H, Ablett MP, Jithesh PV, McKeen HD, Bennett R, Donley C, Kissenpfennig A, McIntosh S, McCarthy HO, O'Neill E, Clarke RB, Robson T. McClements L, et al. Among authors: jithesh pv. Clin Cancer Res. 2013 Jul 15;19(14):3881-93. doi: 10.1158/1078-0432.CCR-13-0595. Epub 2013 Jun 5. Clin Cancer Res. 2013. PMID: 23741069
47 results